Quale sarebbe il prezzo per Moleculin Biotech, Inc. (MBRX)

Il prezzo per Moleculin Biotech, Inc. (MBRX) è $0.6155

Qual è la capitalizzazione di mercato per Moleculin Biotech, Inc. (MBRX)

La capitalizzazione di mercato per Moleculin Biotech, Inc. (MBRX) è $3.28M

Moleculin Biotech, Inc. (MBRX) Rapporto P/S

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs. WP1066, a prominent immune/transcription modulator for the company, is presently in Phase I studies, targeting both adult and pediatric brain tumors, pancreatic cancer, and other types of aggressive malignancies. Further, the firm is developing WP1220, an analog of WP1066, intended for topical application in treating cutaneous T-cell lymphoma. Another compound, WP1122, is under development for glioblastoma multiforme and COVID-19. Moleculin Biotech has established collaboration agreements and partnerships with organizations such as MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. The company was founded in 2015 and maintains its principal offices in Houston, Texas.

Anno	Rapporto P/S	Cambia
Non abbastanza dati per le date fornite.

Anno

Rapporto P/S

Cambia

Non abbastanza dati per le date fornite.

Azienda	Rapporto P/S	Differenza del rapporto P/S	Il paese
Vertex Pharmaceuticals Incorporated VRTX.US	10.17	-	US
Argenx SE ARGX.US	10.13	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	4.74	-	BE

Azienda

Rapporto P/S

Differenza del rapporto P/S

Il paese